@article{5dad832842a84c829fa1daa58122ad6d,
title = "Which trial do we need? How to treat Pseudomonas aeruginosa bacteraemia—proposal for an umbrella randomized controlled trial",
keywords = "Antibiotic resistance, Ceftazidime, Piperacillin-tazobactam, Pseudomonas aeruginosa, β-Lactam",
author = "Mayan Gilboa and {van Duin}, David and Dafna Yahav",
note = "Funding Information: MG and DY declare that they have no conflicts of interest. DvD has received grants from the NIH , Merck , and Shiongi. He has received consulting fees from Actavis , Tetraphase , Sanofi-Pasteur , Medimmune , Astellas , Merck , Allergan , T2Biosystems , Roche , Achaogen , Neumedicine , Pfizer , Entasis , Qpe , Wellspring , Karius , Utility , and Union . He has received payment for lectures from Pfizer, and he has a paying role in the British Society for Antimicrobial Chemotherapy. ",
year = "2023",
month = jul,
doi = "10.1016/j.cmi.2023.03.029",
language = "אנגלית",
volume = "29",
pages = "829--831",
journal = "Clinical Microbiology and Infection",
issn = "1198-743X",
publisher = "Elsevier B.V.",
number = "7",
}